An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 Monotherapy and in Combination With Pembrolizumab in Participants With KRAS G12C Mutated Advanced Solid Tumors | Arctuva